Cystic Fibrosis: the era of personalized treatments

19 février 2025

#CysticFibrosis #PrecisionMedicine #Lungs #Diagnosis #PersonalizedTherapy Cystic fibrosis is a hereditary disease caused by mutations in the CFTR gene, leading to a dysfunction in chloride ion transport. This defect results in the production of thick and sticky mucus in multiple organs, particularly the lungs and digestive system. The accumulation of mucus promotes chronic lung infections, inflamm

#CysticFibrosis #PrecisionMedicine #Lungs #Diagnosis #PersonalizedTherapy

Cystic fibrosis is a hereditary disease caused by mutations in the CFTR gene, leading to a dysfunction in chloride ion transport. This defect results in the production of thick and sticky mucus in multiple organs, particularly the lungs and digestive system. The accumulation of mucus promotes chronic lung infections, inflammation, and severe digestive disorders, progressively reducing both the quality of life and life expectancy of patients.

Current treatments are mainly symptomatic: antibiotics for pulmonary infections, pancreatic enzymes to aid digestion, and respiratory physiotherapy to clear the airways. While these approaches improve patients' daily lives, they do not correct the underlying genetic defect.

Thanks to recent advancements, new therapeutic strategies are emerging. CFTR modulators, which partially restore the function of the defective protein, have already transformed the management of many patients. Other innovative approaches, such as gene editing and RNA-based therapies, pave the way for more targeted and personalized treatments, offering hope for improved management tailored to each patient’s genetic profile.

This study was initiated to identify emerging biomarkers of cystic fibrosis, improve diagnosis, optimize patient monitoring, and promote the development of more personalized treatments.

Biomarkers for Better Cystic Fibrosis Treatment?

To improve the detection of CFTR mutations and refine disease monitoring, researchers have explored advanced genetic sequencing, mass spectrometry, and electrochemical biosensors. Multi-omics approaches combining transcriptomics, proteomics, and microbiomics have also been studied to ensure a deeper understanding of individual patient profiles.

Findings indicate that new technologies improve early detection of cystic fibrosis at birth. Miniaturized sweat sensors and multi-omics analyses enable faster and more precise diagnosis. Therapeutically, CFTR modulators provide significant benefits by correcting underlying genetic defects. Furthermore, emerging strategies such as CRISPR-based genome editing and messenger RNA therapies present promising perspectives for curative treatments.

Read next: Cystic Fibrosis: Could the Microbiome Change Everything?

Toward precision medicine for cystic fibrosis

Cystic fibrosis is a rare genetic disease that disrupts chloride ion transport, leading to thick mucus buildup in the lungs and digestive tract. This abnormality fosters chronic lung infections, persistent inflammation, and pancreatic insufficiency, progressively compromising patients’ quality of life and life expectancy.

This study explored the role of emerging biomarkers and novel detection technologies in personalizing cystic fibrosis management. Identifying precise biological signatures could help tailor treatments based on individual responses, reducing unnecessary side effects and improving the effectiveness of existing therapies.

The results highlight the potential of biomarkers in monitoring disease progression and adjusting treatments, offering a more targeted and effective approach. However, managing cystic fibrosis remains complex and inconsistent. Standard treatments are not effective for all patients, especially those with rare mutations or severe forms of the disease. Additionally, tailoring therapies to each genetic profile remains a challenge. New tools are therefore needed to refine diagnosis and optimize therapeutic strategies.

Read next: Benzbromarone, a new therapy to combat cystic fibrosis

Reserved for healthcare professionals, free registration.

Scientific reference

Addissouky, T. A., et al. (2024). Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis. Journal of Rare Diseases, 3(1), 28

Voir la source

Autres articles récents

Does Nicotinamide Really Prevent Skin Cancer?

1 juillet 2026

Exercising in Extreme Heat: How Can Performance Be Preserved While Reducing Health Risks?

29 juin 2026

Oropouche Virus: A New Threat to Monitor During Pregnancy?

26 juin 2026

Toute la revue de presse